Jessica Hassel
Jessica Hassel
Unknown affiliation
Verified email at
Cited by
Cited by
Improved survival with ipilimumab in patients with metastatic melanoma
FS Hodi, SJ O'day, DF McDermott, RW Weber, JA Sosman, JB Haanen, ...
New England Journal of Medicine 363 (8), 711-723, 2010
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ...
New England journal of medicine 372 (4), 320-330, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ...
The lancet oncology 16 (4), 375-384, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ...
Science 350 (6257), 207-211, 2015
Improved survival with MEK inhibition in BRAF-mutated melanoma
KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ...
New England Journal of Medicine 367 (2), 107-114, 2012
Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis
DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ...
JAMA oncology 4 (12), 1721-1728, 2018
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
LM Kranz, M Diken, H Haas, S Kreiter, C Loquai, KC Reuter, M Meng, ...
Nature 534 (7607), 396-401, 2016
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ...
New England Journal of Medicine 375 (19), 1845-1855, 2016
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
EM Van Allen, N Wagle, A Sucker, DJ Treacy, CM Johannessen, ...
Cancer discovery 4 (1), 94-109, 2014
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ...
Annals of Oncology 28 (2), 368-376, 2017
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
L Hofmann, A Forschner, C Loquai, SM Goldinger, L Zimmer, S Ugurel, ...
European journal of cancer 60, 190-209, 2016
Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ...
JAMA oncology 2 (2), 234-240, 2016
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
U Sahin, P Oehm, E Derhovanessian, RA Jabulowsky, M Vormehr, ...
Nature 585 (7823), 107-112, 2020
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab
B Weide, A Martens, JC Hassel, C Berking, MA Postow, K Bisschop, ...
Clinical Cancer Research 22 (22), 5487-5496, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
L Zimmer, SM Goldinger, L Hofmann, C Loquai, S Ugurel, I Thomas, ...
European journal of cancer 60, 210-225, 2016
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab
A Martens, K Wistuba-Hamprecht, MG Foppen, J Yuan, MA Postow, ...
Clinical Cancer Research 22 (12), 2908-2918, 2016
Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis
SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ...
Journal of Clinical Oncology 35 (2), 226, 2017
Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label …
J Larkin, D Minor, S D'Angelo, B Neyns, M Smylie, WH Miller Jr, ...
Journal of clinical oncology 36 (4), 383, 2018
Overall survival benefit with tebentafusp in metastatic uveal melanoma
P Nathan, JC Hassel, P Rutkowski, JF Baurain, MO Butler, M Schlaak, ...
New England Journal of Medicine 385 (13), 1196-1206, 2021
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
TK Eigentler, JC Hassel, C Berking, J Aberle, O Bachmann, V Grünwald, ...
Cancer treatment reviews 45, 7-18, 2016
The system can't perform the operation now. Try again later.
Articles 1–20